BioSpace News Archive

Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2021 after the market closes on Tuesday, April 20, 2021 , and will host a conference call at 5:30 p.m. ET that day to discuss those results.

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company today announced that IMV’s executive management team will be participating in the 2021 Bloom Burton & Co. Healthcare Investor Virtual Conference which will be held April 20 and April 21, 2021.

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will present at the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference on Tuesday, April 20, 2021

- Company to further expand its DECODE™ discovery platform, accelerate multiple oncology clinical programs, and advance discovery programs in oncology, autoimmune disorders, infectious disease, and other serious diseases

Athersys, Inc. will release its first quarter 2021 financial results at approximately 4:00 PM Eastern Time on Thursday, May 6, 2021, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results.

908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced that Michele Fournier has joined the company as Chief People Officer. Bringing more than thirty years of global human resources experience in corporate and consulting roles

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health’s President and Chief Executive Officer, will present a corporate overview of the Company at the Bloom Burton & Co. Healthcare Conference

Castle Biosciences Announces Prospective, Multi-Center Publication Demonstrating DecisionDx ® -Melanoma as Significant, Independent Predictor of Patient Outcomes in Cutaneous Melanoma Study published in JCO Precision Oncology

Company Announces Appointment of Jeffery Lichtenhan, Ph.D., to Lead Efforts in Hearing Diagnostics and Measurement; Joins Frequency from Washington University Medical School in St. Louis

AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced new additions to its leadership team with the appointments of Paul Herzich as Chief Technology Officer and Jared Simons as Vice President of Manufacturing.